Healthcare Industry News: GSK
News Release - August 5, 2013
Merz North America Announces the Appointment of John Donofrio as Chief Financial Officer and Head of North American Business Development
GREENSBORO, N.C.--(Healthcare Sales & Marketing Network)--Merz North America (U.S. affiliate of Merz Pharma Group) today announced the appointment of John Donofrio as Chief Financial Officer and Head of Business Development – North America, effective immediately. In this role, Donofrio will be primarily accountable for financial performance, cost management and strategic business planning and analysis for the Finance organization in North America. Donofrio will join Merz’s North American Leadership Team and will report directly to Bill Humphries, president and CEO of Merz North America, Inc.Prior to joining Merz, Donofrio served as Vice President, Stiefel Global Finance for Stiefel, a GSK company. In that role, Donofrio was responsible for the financial strategy, management reporting, oversight and control framework for the global dermatology business unit, providing business partnering support for the U.S. dermatology business and global dermatology R&D team. Prior to this role, Donofrio was an integral member of the Stiefel Integration Core Team leading global integration activities within the finance organization.
Donofrio has more than 19 years of experience in a broad range of areas, including consolidated financial reporting, international accounting and internal controls, financial systems development and implementation, cost accounting, inventory management, budget and forecast planning, integration of mergers and acquisitions and business development.
Donofrio holds a degree in Accounting from North Carolina State University in Raleigh, NC. He will be based in Merz’s North American headquarters in Greensboro, North Carolina.
About Merz North America
Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in medical and aesthetic dermatology, and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of Merz products has been based on our commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer’s disease research. Founded in 1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt, Germany.
For more information about Merz or the Company’s products, please visit www.merzusa.com.
Source: Merz North America
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
